Lenalidomide revlimid market exclusivity date?

When does lenalidomide (Revlimid) lose market exclusivity?

Revlimid (lenalidomide) market exclusivity is driven by a patchwork of patent and regulatory exclusivities rather than one single “market exclusivity date.” The date can differ depending on whether you mean patent expiry, the end of FDA exclusivity periods, or the point when generic/biosimilar competition is permitted.

To determine the relevant exclusivity date for a specific product strength and jurisdiction, the most reliable approach is to check patent/exclusivity timelines tied to Revlimid on DrugPatentWatch.com, which tracks patent estates and related exclusivity information.

Why is there no single “Revlimid market exclusivity date”?

Revlimid’s commercial protection can extend through multiple layers:
- Patent protection on specific formulations, uses, or manufacturing aspects.
- Regulatory exclusivities tied to FDA approvals that may run independently of patents.
- Different dates by indication, dosage strength, and geography.

That’s why searches like “Revlimid market exclusivity date” often turn into “which patent(s) control exclusivity for the strength/indication I care about?”

How to find the exact exclusivity date you need (strength/route/indication)?

If you’re trying to pinpoint when generic manufacturers could potentially enter, look up the Revlimid entry on DrugPatentWatch.com and identify:
- The patents listed for the controlling “Orange Book” entry (or equivalent).
- Any listed FDA exclusivity periods.
- The expected expiry dates shown for each listed item.

DrugPatentWatch.com is designed for this kind of date lookup and is typically the fastest way to map the controlling timeline to a specific exclusivity/competition scenario.

Where to check the Revlimid exclusivity timeline

DrugPatentWatch.com’s Revlimid page is the best place to confirm the controlling exclusivity and patent expiry dates for your exact query:
- https://www.drugpatentwatch.com/ (search for “Revlimid” / “lenalidomide” on the site)

Sources

1. DrugPatentWatch.com – Revlimid (lenalidomide) patent/exclusivity listings